Holen Sie sich die Stockscreener-App
0.8257
2.47%
-0.0209
Handel nachbörslich:
.83
0.0043
+0.52%
Schlusskurs vom Vortag:
$0.8466
Offen:
$0.8436
24-Stunden-Volumen:
1.06M
Relative Volume:
1.37
Marktkapitalisierung:
$103.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.91M
KGV:
-3.7532
EPS:
-0.22
Netto-Cashflow:
$-19.57M
1W Leistung:
-8.63%
1M Leistung:
-20.61%
6M Leistung:
-40.60%
1J Leistung:
+0.32%
1-Tages-Spanne:
$0.8215
$0.8585
1-Wochen-Bereich:
$0.8215
$0.939
52-Wochen-Spanne:
$0.7744
$2.31
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
10202 5TH AVENUE NE, SEATTLE, WA
Vergleichen Sie ATOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.8257 | 103.87M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Jane Street Group LLC Trims Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (NASDAQ: ATOS) vs. NLS Pharmaceutics (NASDAQ: NLSP): A Comparative Analysis - HPBL
Head-To-Head Analysis: Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World
The Hidden Connection: Dr. Steven Quay on Alcohol and Cancer Risk - Cville Right Now
Atossa Therapeutics Applauds U.S. Surgeon General’s - GlobeNewswire
Surgeon General Links Alcohol to 44,000 Annual Breast Cancer Cases, Atossa Backs Warning - StockTitan
Geode Capital Management LLC Has $4.28 Million Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Barclays PLC Has $255,000 Stock Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
State Street Corp Has $2.63 Million Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Decrease in Short Interest - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by XTX Topco Ltd - Defense World
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
The Manufacturers Life Insurance Company Invests $75,000 in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Update - MarketBeat
Atossa Therapeutics’ (ATOS) Buy Rating Reiterated at HC Wainwright - Defense World
Atossa Therapeutics to present poster on Z-endoxifen at SABCS - Yahoo Finance
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium - The Manila Times
Atossa Therapeutics to Present Poster Describing the - GlobeNewswire
Atossa Therapeutics Unveils Breakthrough Cancer Research: New Drug Combinations Show Enhanced Tumor-Fighting Power - StockTitan
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density - The Manila Times
Atossa Therapeutics Announces Full Results from Phase 2 - GlobeNewswire
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically - EIN News
Atossa Therapeutics announces three posters on Phase 2 EVANGELINE trial - TipRanks
Atossa Therapeutics to Present Pharmacokinetic and - GlobeNewswire
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 - EIN News
Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $7.00 at Ascendiant Capital Markets - Defense World
Atossa Therapeutics (NASDAQ:ATOS) Given New $7.00 Price Target at Ascendiant Capital Markets - MarketBeat
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research - The Manila Times
Atossa Therapeutics Presents Data from Study Investigating - GlobeNewswire
Atossa's New Breast Cancer Compounds Show Promising Anti-Cancer Activity in Latest Research - StockTitan
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research - The Manila Times
Atossa Therapeutics to Present New Cancer Treatment Research at AACR Conference | ATOS Stock News - StockTitan
Atossa Therapeutics announces five abstracts on Z-endoxifen - TipRanks
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium - The Manila Times
Atossa's Endoxifen Breast Cancer Drug Data to Be Showcased at Major SABCS Conference | ATOS Stock News - StockTitan
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ATOS FY2024 EPS Estimate Increased by Cantor Fitzgerald - MarketBeat
What is HC Wainwright's Estimate for ATOS FY2026 Earnings? - MarketBeat
Atossa Therapeutics Inc (ATOS) Quarterly 10-Q Report - Quartz
Atossa Genetics stock target lifted, retains buy on positive study results - Investing.com UK
Atossa Therapeutics: Q3 2024 Financial Results and Updates - TipRanks
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Simply Wall St
Atossa Therapeutics (NASDAQ:ATOS) Downgraded to “Sell” Rating by StockNews.com - Defense World
Atossa Therapeutics (NASDAQ:ATOS) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go - Seeking Alpha
Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Atossa Genetics shares hold Buy rating on positive trial results By Investing.com - Investing.com Canada
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):